Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multispecific T Cells for Chemo-Refractory Viral Infections After Allogeneic Stem Cell Transplantation
DRKS00018985Phase 3Recruiting
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Dec 2019
- Modality
- Cell Therapies
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus disease (CMV), Epstein-Barr virus infection and adenoviral infection comparing Multivirus-specific T cells with Placebo (NaCl) (2 arms). Started Dec 2019; status: recruiting.
02
Drugs
HLA-matched multivirus-specific T cells
03
Conditions
cytomegalovirus disease (CMV)Epstein-Barr virus infectionadenoviral infection
Beyond the preview
Go deeper on DRKS00018985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00018985.